Welcome to DukeHealth.org.
Skip over navigation
  • Home
  • Patient and Visitor Info
  • Physicians
  • Services
  • Clinical Trials
  • Event Calendar
  • Locations
  • Health Library
  • About Duke Medicine

Quick Links

  • Appointments
  • HealthView Patient Login
  • Quality and Safety
Home > Clinical Trials > An Evaluation of the Safety and Efficacy of the Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso
Jumbo Large Regular Text:
Print
Clinical Trials

An Evaluation of the Safety and Efficacy of the Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso

Related Content

Health Articles

  • Understanding Clinical Trials: A participants' guide

In This Section

Related Clinical Trials

  • Pulmonology and Respiratory Medicine

Share

This is a multicenter open-label 24-week study to evaluate the safety and tolerability of the addition of UT-15C SR to pulmonary arterial hypertension patients currently receiving Tyvaso.

For more information, contact Melissa Willis, RN at 919-684-6237.


(REF# 30717)
Contact Us | Careers | Privacy Policy | Make a Gift | Site Map | RSS Feeds | En EspaƱol | Mobile Site | Help
Duke Medicine | Duke School of Medicine | Duke Children's | Duke University
Toll-Free: 888-ASK-DUKE (888-275-3853)
Copyright © 2004-2013 Duke University Health System

About This Page

Updated: Feb. 22, 2012
Published: Feb. 22, 2012
URL: http://www.dukehealth.org/clinicaltrials/ut15c-sr-to-pah-patients-receiving-tyvaso